Biostar Pharmaceuticals, Inc.
119 articles about Biostar Pharmaceuticals, Inc.
-
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
6/15/2023
Biostar Pharma, Inc. is pleased to announce that, after having in-depth discussions with the FDA through pre-IND meetings, the FDA has approved the IND of a phase 2/3 clinical trial with seamless protocol design for the company's core product utidelone injectable in patients with locally advanced or metastatic non-small cell lung cancer.
-
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug
6/12/2023
Biostar Pharma, Inc. is pleased to announce that the first patient has been enrolled today for a Phase 1 clinical study (BG02-2201; NCT05681000) of its proprietary oral formulation product of utidelone, UTD2 (utidelone capsule) in advanced solid tumor patients in the US.
-
Biostar Regains Compliance With NASDAQ Continued Listing Requirement
12/5/2017
Biostar announced that on November 30, 2017, it received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it regained compliance with NASDAQ's Listing Rule 5250 for continued listing on NASDAQ Capital Market and the Staff considers the matter closed.
-
Biostar Pharma Announces its Quarterly Results for Nine Months Ended September 30, 2017
11/21/2017
The Company had no sales on all Aoxing Pharmaceutical products in the third fiscal quarter ended September 30, 2017 as Aoxing Pharmaceutical temporarily stopped production to conduct maintenance of its production lines to renew its GMP certificates.
-
Biostar Pharma Announces Its Quarterly Results for Three Months Ended June 30, 2017
11/16/2017
Biostar Pharma today announced its financial results for second quarter ended June 30, 2017.
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results For Three Months Ended March 31, 2017
5/22/2017
-
Biostar Pharmaceuticals, Inc. Announces Its Annual Results For The Year Ended December 31, 2016
4/14/2017
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended September 30, 2016
11/22/2016
-
Biostar Pharmaceuticals, Inc. Skyrockets On New Chinese Product Launch
10/12/2016
-
Biostar Pharmaceuticals, Inc. Completes Previously Announced Registered Direct Financing
10/4/2016
-
Biostar Pharmaceuticals, Inc. Signs A Letter Of Intent To Acquire Xianyang Yongsheng Health Products Co., Ltd.
9/22/2016
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results For Three Months Ended June 30, 2016
8/23/2016
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results For Three Months Ended March 31, 2016
5/24/2016
-
Biostar Pharmaceuticals, Inc. Announces Its Annual Results For The Year Ended December 31, 2015
4/15/2016
-
Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price
2/24/2016
-
Biostar Pharmaceuticals, Inc. Airs Advertisements For Its Analgesic (Pain Relief) Cream On China's CCTV
2/16/2016
-
Biostar Pharmaceuticals, Inc. To Effect Reverse Stock Split
2/5/2016
-
Biostar Pharmaceuticals, Inc. Postpones Its 2015 Annual Meeting Of Shareholders
12/7/2015
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly And Half Year Results For 2015
8/20/2015
-
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results For Three Months Ended March 31, 2015
5/18/2015